Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: PCSS who wrote (2278)	11/17/2004 7:52:15 PM
From: software salesperson	Respond to of 3044

r&d day 11/16/04 the problem with the audio in part 2 on mlnm’s site has finally been fixed. 1) one gets a real feel for how challenging portfolio balancing must be 2) an interesting discussion of how their use of biomarkers with play out in their upcoming trials and in personalized medicine in the future 3) a lot of new, ambitious work preclinically 4) dropped from the pipeline were 519 (stroke), 591rl (prostate) and 944/576(solid tumors) 5) doesn’t look like there will be any new molecular entities in clinic in 2004 6) possibilities for 2005 are 3701(backup to 3897 - - RA), 1202 (MS), 8054( aurora protein kinase for all solid tumors) 7) earliest 02( UC) will be back in clinic is 2006 8) renegotiating aventis deal in 2005 impressions although what they are trying to do preclinically sounds great, it was disappointing that nothing new will be in the clinic in 2004 and, aside from the backup, only one new entity is likely to appear in 2005. although they didn’t say anything specifically, I’m sensing that it’s about time for a new partnership in 2005. it certainly sounds like they will reach non-gaap profitability in 2006. sales